URINARY PODOCALYXIN - BIOMARKER FOR PREDICTION OF PREECLAMPSIA

Irena Kostovska (1), Katerina Tosheska Trajkovska (1), Svetlana Cekovska (1), Goce Spasovski (2), Ognen Kostovski (3), Danica Labudovik (1)

Department of medical and experimental biochemistry, Ss. Cyril and Methodius University, Skopje, North Macedonia
Department of Nephrology, Ss. Cyril and Methodius University, Skopje, North Macedonia
University Clinic of Abdominal surgery, Medical Faculty, Skopje, North Macedonia

Introduction

Preeclampsia is a multi-system disorder of pregnancy, which is characterized by new onset hypertension (systolic and diastolic blood pressure of ≥ 140 and 90 mm Hg, respectively, on two occasions, at least 6 hours apart) and proteinuria (protein excretion of ≥ 300 mg in a 24 h urine collection, or a dipstick of ≥ 2+), that develop after 20 weeks of gestation in previously normotensive women. PE is one of the most common complication in pregnancy, affecting 5-7% of all pregnancies. Urinary excretion of podocyte cells and podocyte specific proteins such as podocalyxin suggesting that podocytopathy have a important role in pathogenesis of PE.

The aim of this study was to test the significance of urinary podocalyxin in prediction of PE.

Material and methods

In our study were enrolled 101 pregnant women. We divided all pregnant women into three groups: pregnant women with high risk of development of PE (women with high-risk pregnancy) n=41, pregnant women n=30, as a control group. Half of subjects into groups were in second trimester, half in third trimester of pregnancy. As material we used first morning urine and venous blood. Podocalyxin in urine was measured by immunoenzyme assay, microalbumin in urine was measured with turbidimetric method and urinary creatinine with photometric method. In blood sera, we measured a few standard biochemical parameters. Statistical analyses were perform using SPSS version 22.

Results

Table 1. Clinical characteristics of pregnant women

	Pregnant	Women with		p
	women with PE	high risk pregnancy	pregnant women	Value
Age (years)	27.7±4.7	29.1±5.6	29.4±6.0	0.376
BMI (kg/m²)	29.3±4.6	29.9±3.6	25.7±3.3	<10-3
Glucose (mmol/L)	5.2±0.5	5.9±1.2	4.6±0.5	<10-3
SBP mm/Hg	151.8±13.8	145.6±26.6	119±5.4	<10-3
DBP mm/Hg	95.1±7.4	90.1±13	77.3±6.0	<10-3
Total protein (g/L)	67.6±7.2	69±6.2	68.3±5.5	0.562
Albumin (g/L)	34.2±5.1	35.4±4.7	39.1±4.1	0.001
Urea (mmol/L)	5.5±1.2	6.3±2.3	5.0±1.9	0.045
Creatinine (µmol/L)	70.7±9.2	69.4±11.9	56.8±4.6	<10-3
eGFR (ml min ⁻¹ 1.73 m ⁻²)	91.3±15.1	97.5±26.9	95.5±9.6	0.372
Podocalyxin in urine (ng/ml)	164.3±93.1	98.7±75.4	27.2±28.8	<10-3

BMI-body mass index, SBP-systolic blood pressure, DBP-diastolic blood pressure eGFR-estimated glomerular filtration rate

Table 2. Comparison of concentration of urinary podocalyxin between pregnant woman with high risk and women with PE in second trimester (II) and in third trimester (III)

	Mean	SD	Median	p value
High risk women (II)	96	79	66	
PE women (II)	167	115	119	<10-3
High risk women (III)	102	71	76	
PE women (III)	163	80	158	<10-3

Figure 1. Concentration of urinary podocalyxin between groups of pregnant women



Figure 2. Percent of pregnant women with elevated urinary podocalyxin in groups





Figure 3. Correlation between urinary podocalyxin and eGFR (r =- 0.194; p=0.051)



Figure 4. Correlation between urinary podocalyxin and gestational age (r =0.259; p=0.009)



Figure 5. ROC analysis for urinary podocalyxin in women with PE



Conclusions

Urinary podocalyxin could be useful marker for prediction of preeclampsia, due to these findings:

√high percent of women with PE and women with high risk pregnancy with elevated levels of urinary podocalyxin,

✓ significant differences in concentration of urinary podocalyxin between groups of women and between groups of women in second and third trimester

regative correlation between urinary podocalyxin concentration and eGFR and positive correlation between urinary podocalyxin and gestational age

√high sensitivity and specificy and high predicted probability of urinary podocalyxin in pregnant women with PE.